Jieke Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jieke Yan has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Bin Liu
Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy Jiangsu Ocean University Lianyungang China
1 shared publication - Changjun Wang
Interventional Oncology Institute, Shandong University, Jinan, PR of China
1 shared publication ChaoYuan Song
Central Hospital Zibo China
1 shared publicationDeYan Cao
Department of Neural Medicine Cheeloo College of Medicine The Second Hospital Shandong University Jinan China
1 shared publication- Haiyang Chang
University of Guelph
1 shared publication - Hong‐Wei Wang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Hepatopancreatobiliary Surgery Department I, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing, 100142, China
1 shared publication
Latest Publications
- 20 October 2020
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 48 (3) , 355-360
Effect of orexin‐A on mitochondrial biogenesis, mitophagy and structure in HEK293‐APPSWE cell model of Alzheimer's disease
Mitochondrial dysfunction plays a key role in the pathogenesis and progression of Alzheimer's Disease (AD). Our previous studies showed that over expression of AD‐associated mutant β‐amyloid precursor protein (APP) led to abnormalities of mitochondrial biogenesis and mitophagy, leading to mitochondrial dysfunction. However, the mechanism remains unclear. In this study, we investigated the effect of orexin‐A on mitochondrial biogenesis, mitophagy and mitochondrial structure in overexpression of AD‐associated mutant APP cells. We used 20E2 cells as the AD cell model. 20E2 cells were treated with orexin‐A (50, 100 nmol/L). The effect of different concentrations of orexin‐A on cell activity was detected by MTT. As compared with the non‐treated 20E2 cells, orexin‐A‐treated 20E2 cells showed increased expression of APP, decreased cell viability and decreased adenosine triphosphate (ATP) level, decreased levels of regulatory proteins of mitochondrial biogenesis (peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha [PGC‐1α], nuclear respiratory factor 1/2 [NRF1/2], mitochondrial transcription factor A [TFAM]), increased levels of regulatory proteins of mitophagy (Parkin, PTEN‐induced putative kinase 1 [PINK1], microtubule‐associated protein light chain 3 II/I [LC3‐II/LC3‐I]) and decreased p62 level, with damaged mitochondrial structure. Orexin‐A may reduce mitochondrial biogenesis, enhance mitophagy and damage mitochondrial structure in AD.
- 20 October 2020
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 48 (3) , 355-360
Effect of orexin‐A on mitochondrial biogenesis, mitophagy and structure in HEK293‐APPSWE cell model of Alzheimer's disease
Mitochondrial dysfunction plays a key role in the pathogenesis and progression of Alzheimer's Disease (AD). Our previous studies showed that over expression of AD‐associated mutant β‐amyloid precursor protein (APP) led to abnormalities of mitochondrial biogenesis and mitophagy, leading to mitochondrial dysfunction. However, the mechanism remains unclear. In this study, we investigated the effect of orexin‐A on mitochondrial biogenesis, mitophagy and mitochondrial structure in overexpression of AD‐associated mutant APP cells. We used 20E2 cells as the AD cell model. 20E2 cells were treated with orexin‐A (50, 100 nmol/L). The effect of different concentrations of orexin‐A on cell activity was detected by MTT. As compared with the non‐treated 20E2 cells, orexin‐A‐treated 20E2 cells showed increased expression of APP, decreased cell viability and decreased adenosine triphosphate (ATP) level, decreased levels of regulatory proteins of mitochondrial biogenesis (peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha [PGC‐1α], nuclear respiratory factor 1/2 [NRF1/2], mitochondrial transcription factor A [TFAM]), increased levels of regulatory proteins of mitophagy (Parkin, PTEN‐induced putative kinase 1 [PINK1], microtubule‐associated protein light chain 3 II/I [LC3‐II/LC3‐I]) and decreased p62 level, with damaged mitochondrial structure. Orexin‐A may reduce mitochondrial biogenesis, enhance mitophagy and damage mitochondrial structure in AD.
- 19 December 2016
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 51 (1) , 4-11
Interventional Therapy for Transplant Renal Artery Stenosis Is Safe and Effective in Preserving Allograft Function and Improving Hypertension
To evaluate the outcomes of percutaneous intervention (PI) for transplant renal artery stenosis (TRAS). Doppler ultrasonography was used as the screening tool, and angiography was the diagnostic method for TRAS. The indications for PI were (1) a reduction in lumen diameter of >50% or (2) a mean pressure gradient of >15 mm Hg. Technical success was assessed immediately after the procedure. The short-term results of stenosis were evaluated by serum creatinine (Scr) levels and blood pressure (BP). The long-term results were assessed by graft survival and renal function. From October 2009 to July 2015, a total of 660 patients had kidney transplantation and 22 cases underwent PI. The technical success was 100%. The mean Scr level preintervention was 321.6 ± 167.2 (range, 171.3-862.0) μmol/L, and it decreased to 145.3 ± 44.7 (range, 74.3-260.8) μmol/L 1 month postintervention (P < .001). Blood pressure was also improved at 1 month postintervention, as assessed by systolic (157.0 ± 13.0 vs 131.0 ± 11.0 mm Hg, P < .001), diastolic (95.0 ± 5.0 vs 77.0 ± 9.0 mm Hg, P < .001), and mean arterial pressure (116.0 ± 7.0 vs 95.0 ± 9.0 mm Hg, P < .001). The patency rate was 100%, 91.7%, and 85.7% at 1, 3, and 12 months, respectively. The secondary patency rate was 100%. Graft survival was 100% during follow-up. There was no significant deterioration in graft function or BP (P > .05) postintervention when compared to posttransplantation. Percutaneous intervention for TRAS is safe and results in significant improvement both in allograft function and in BP.
- 19 December 2016
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 51 (1) , 4-11
Interventional Therapy for Transplant Renal Artery Stenosis Is Safe and Effective in Preserving Allograft Function and Improving Hypertension
To evaluate the outcomes of percutaneous intervention (PI) for transplant renal artery stenosis (TRAS). Doppler ultrasonography was used as the screening tool, and angiography was the diagnostic method for TRAS. The indications for PI were (1) a reduction in lumen diameter of >50% or (2) a mean pressure gradient of >15 mm Hg. Technical success was assessed immediately after the procedure. The short-term results of stenosis were evaluated by serum creatinine (Scr) levels and blood pressure (BP). The long-term results were assessed by graft survival and renal function. From October 2009 to July 2015, a total of 660 patients had kidney transplantation and 22 cases underwent PI. The technical success was 100%. The mean Scr level preintervention was 321.6 ± 167.2 (range, 171.3-862.0) μmol/L, and it decreased to 145.3 ± 44.7 (range, 74.3-260.8) μmol/L 1 month postintervention (P < .001). Blood pressure was also improved at 1 month postintervention, as assessed by systolic (157.0 ± 13.0 vs 131.0 ± 11.0 mm Hg, P < .001), diastolic (95.0 ± 5.0 vs 77.0 ± 9.0 mm Hg, P < .001), and mean arterial pressure (116.0 ± 7.0 vs 95.0 ± 9.0 mm Hg, P < .001). The patency rate was 100%, 91.7%, and 85.7% at 1, 3, and 12 months, respectively. The secondary patency rate was 100%. Graft survival was 100% during follow-up. There was no significant deterioration in graft function or BP (P > .05) postintervention when compared to posttransplantation. Percutaneous intervention for TRAS is safe and results in significant improvement both in allograft function and in BP.